SWOG S1203: A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy Versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)

Guillermo Garcia‐Manero ,Frederick R Appelbaum,David F Claxton,Bruno C Medeiros,Tara L Lin,Mary Lynn Savoie,Anna Moseley,Richard A Larson,Megan Othus,John M Pagel,Jonathan E Kolitz,Guido Marcucci,Mikkael A Sekeres,Min Fang,Stephen A Strickland,James Essell,Jerald P Radich,Harry P Erba,Selina M Luger ,Brian Uy ,David A Rizzieri ,Richard Stone ,Mark R Litzow ,Bayard L Powell ,Sanjay Mohan

doi:10.1182/blood.v128.22.901.901

SWOG S1203: A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy Versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)

Guillermo Garcia‐Manero , Frederick R Appelbaum + Show 23 more

https://doi.org/10.1182/blood.v128.22.901.901

Copy DOI

#Research Funding #Speakers Bureau + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

SWOG S1203: A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy Versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)

Full Text